Biolegend, 329705, PE anti-human CD274 (B7-H1, PD-L1) Antibody, 25tests

CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells.
25tests
Verified Reactivity: Human
Reported Reactivity: African Green, Baboon, Cynomolgus, Rhesus
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Full length human PD-L1
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser: Blue Laser (488 nm)Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes: Clone 29E.2A3 is reported to recognize an epitope on PD-L1 within the PD-L1-CD80 binding region5. Additional reported applications (for the relevant formats) include: blocking1-3 and immunohistochemical staining of acetone-fixed frozen sections1. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329715, 329716, 329745 - 329748). It has been observed that clone 29E.2A3 is able to bind to Alexa Fluor® 700 antibody conjugates during multi-color immunofluorescent staining. This interaction can be resolved by sequentially staining with the 29E.2A3 antibody first and then followed by the Alexa Fluor® 700 conjugate of interest. Clone 29E.2A3 does not work in Western blot applications7.
Application References(PubMed link indicates BioLegend citation): Brown J, et al. 2003. J. Immunol. 170:1257. (FC, IHC, Block) Radziewicz H, et al. 2007. J. Virol. 81:2545. (Block) Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (Block) Barsoum IB, et al. 2014. Cancer Res. 74:665. PubMed Haile, S et al. 2013. J. Immunol. 191:2829. RL M, et al. 2015. PNAS. 112:6506-6514. PubMed Mahoney KM, et al. 2015. Cancer Immunol. Res. 3:1308.
Product Citations: Soday L, et al. 2021. Frontiers in Immunology. 12:600056. PubMed Jiang G, et al. 2020. Aging (Albany NY). 12:11466. PubMed Chen L, et al. 2023. Immunology. 169:204. PubMed Fox DB, et al. 2023. NPJ Precis Oncol. 7:25. PubMed Wu Y, et al. 2023. Nat Cancer. 4:382. PubMed Li D, et al. 2023. Int J Oncol. 62:. PubMed Yi X, et al. 2023. Signal Transduct Target Ther. 8:107. PubMed Yang A, et al. 2023. J Immunother Cancer. 11:. PubMed Lafôrets F, et al. 2023. iScience. 26:106514. PubMed Hu X, et al. 2023. Nat Biotechnol. . PubMed Gu T, et al. 2023. Front Immunol. 14:1145028. PubMed Taylor J, et al. 2023. Front Immunol. 14:1119350. PubMed Shao L, et al. 2021. Cell Death Discov. 7:145. PubMed Cui J, et al. 2022. Cancer Cell Int. 22:72. PubMed Oreskovic E, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed Kumagai Y, et al. 2020. J Surg Res. 246:52. PubMed Zhang Z, et al. 2022. Cancer Gene Ther. 29:722. PubMed Rodda LB, et al. 2022. Cell. 185:1588. PubMed Deepak HB, et al. 2022. Indian J Pharmacol. 54:183. PubMed He Y, et al. 2023. J Transl Med. 21:25. PubMed Hajibabaei S, et al. 2023. Sci Rep. 13:1003. PubMed Zhang W, et al. 2022. Dev Cell. 57:329. PubMed Schott DS, et al. 2017. Oncotarget. 8:72755. PubMed Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed Katsurahara K, et al. 2021. Cancer Sci. 112:1026. PubMed Geuijen C, et al. 2021. Nat Commun. 12:4445. PubMed Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed Sucker A, et al. 2017. Nat Commun. 8:15440. PubMed Huang X, et al. 2021. Nat Nanotechnol. 16:214. PubMed Zhang H, et al. 2021. Cancer Gene Ther. Online ahead of print. PubMed Jarosch S, et al. 2022. STAR Protoc. 3:101374. PubMed Sugawara E, et al. 2020. Autophagy. 1.323611111. PubMed Rosskopf S, et al. 2016. Sci Rep. 6:31580. PubMed Liu Y, et al. 2021. Oncogene. 40:2230. PubMed Fujiwara Y, et al. 2021. Pancreas. 50:405. PubMed Yi K, et al. 2022. Front Immunol. 12:802795. PubMed Mineo M, et al. 2020. Molecular Cell. 78(6):1207-1223.e8. PubMed Guan H, et al. 2016. Sci Rep. 6:35651. PubMed Tran L, et al. 2017. Cancer Immunol Res. 5:1141. PubMed Nduom E, et al. 2016. Neuro Oncology. 18: 195 - 205. PubMed Lin JR et al. 2018. eLife. 7 pii: e31657. PubMed Zong Z, et al. 2019. Front Immunol. 10:1643. PubMed Herter JM, et al. 2022. Strahlenther Onkol. Online ahead of print. PubMed Jutz S, et al. 2016. J Immunol Methods. 430:10-20. PubMed Bryson BD, et al. 2019. Nat Commun. 10:2329. PubMed Lee JM, et al. 2022. Lupus Sci Med. 9:. PubMed Leonard NA, et al. 2021. Cancers (Basel). 13:. PubMed Fan Z, et al. 2020. EMBO Mol Med. 12:e11571. PubMed Rolfes V, et al. 2018. Oncotarget. 9:27460. PubMed Souriant S, et al. 2019. Cell Rep. 26:3586. PubMed Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed Wang Y, et al. 2021. Front Immunol. 12:654463. PubMed El Ahanidi H, et al. 2022. Front Oncol. 11:795242. PubMed Jarosch S, et al. 2021. Cell Rep Methods. 1:100104. PubMed Mao R, et al. 2020. Cancer Sci. 111:3174. PubMed Durand-Panteix S, et al. 2012. J Immunol. 189:181. PubMed Wu L, et al. 2018. Oncol Lett. 15:9507. PubMed Hu H, et al. 2022. Exp Ther Med. 24:487. PubMed Zhang R, et al. 2021. Front Oncol. 10:581733. PubMed Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed Ye LL, et al. 2020. Annals of Translational Medicine. 8(24):1647. PubMed Su S et al. 2018. Cell. 175(2):442-457 . PubMed Bouleau A, et al. 2022. J Nucl Med. 63:1259. PubMed Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed Houtsma R, et al. 2021. STAR Protoc. 2:100864. PubMed Okita R, et al. 2021. Thorac Cancer. 12:775. PubMed Iwasa M, et al. 2019. Oncotarget. 10:1903. PubMed Richardson JR, et al. 2018. Front Immunol. 2.182638889. PubMed Yoshino H, et al. 2021. Curr Issues Mol Biol. 43:153. PubMed Rydyznski Moderbacher C, et al. 2020. Cell. 183(4):996-1012.e19. PubMed Kim DH, et al. 2019. Exp Mol Med. 51:94. PubMed Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed Curnock AP, et al. 2021. JCI Insight. 6:. PubMed Dan J, et al. 2016. J Immunol. 197: 983 - 993. PubMed Lundell A, et al. 2017. Sci Rep. 7:39904. PubMed Park JA, et al. 2020. J Hematol Oncol. 0.661111111. PubMed Kwak T, et al. 2020. Cell Reports. 33(13):108571. PubMed Zhou C, et al. 2021. Mol Ther. 29:1512. PubMed Ahn A, et al. 2021. Cancers (Basel). 13:. PubMed Tsuchiya K, et al. 2021. Oncoimmunology. 10:1962656. PubMed Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed Rydyznski Moderbacher C, et al. 2022. J Clin Invest. :. PubMed Guo Q, et al. 2022. Blood Adv. 6:5668. PubMed Zhang Z, et al. 2022. Clin Transl Med. 12:e1072. PubMed Ng KW, et al. 2019. eLife. 0.333333333333333. PubMed Lei Y, et al. 2021. Clin Transl Immunology. 10:e1231. PubMed Sam J, et al. 2020. Front Oncol. 10:575737. PubMed Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed Gilardini Montani MS, et al. 2020. Br J Cancer. 123:298. PubMed Xu H, et al. 2010. J Immunol. 185:7340. PubMed Padet L, et al. 2014. Immunobiology. 219:687. PubMed Suzuki D, et al. 2020. Stem Cell Reports. 14:49. PubMed Zhou X, et al. 2022. J Nucl Med. 63:536. PubMed Hu Q, et al. 2021. Nat Biomed Eng. 5:1038. PubMed Lau P, et al. 2022. Cell Mol Immunol. :. PubMed Darga EP, et al. 2021. PLoS One. 16:e0260124. PubMed Zhang H, et al. 2021. Adv Sci (Weinh). 8:2003404. PubMed Liang YH, et al. 2021. J Biomed Sci. 28:75. PubMed Shen C, et al. 2021. BMC Med. 19:283. PubMed Kenty JH, et al. 2021. STAR Protocols. 2(3):100675. PubMed Zhang C, et al. 2020. Front Oncol. 0.944444444. PubMed Ye Y, et al. 2020. Genome Med. 0.557638889. PubMed Tsukamoto M, et al. 2019. Cancer Sci. 110:310. PubMed Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed Wang H, et al. 2022. J Cancer. 13:2126. PubMed
RRID: AB_940366 (BioLegend Cat. No. 329705) AB_940368 (BioLegend Cat. No. 329706)
Distribution: T cells, B cells, NK cells, monocytes/macrophages, granulocytes and dendritic cells
Function: CD274 is involved in the costimulatory signal, essential for T lymphocyte proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-CD1-independent manner. Its interaction with PD-1-CD1 inhibits T-cell proliferation and cytokine production.
Ligand/Receptor: PD-1 (PDCD1)
Cell Type: B cells, Dendritic cells, Fibroblasts, Granulocytes, Macrophages, Monocytes, NK cells, T cells
Biology Area: Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family: Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References: 1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.
Gene ID: 29126
UniProt: View information about CD274 on UniProt.org
Clone: 29E.2A3
Regulatory Status: RUO
Other Names: Programmed cell death ligand 1 (PD-L1), B7 homolog 1 (B7-H1)
Isotype: Mouse IgG2b, κ
Q: What type of PE do you use in your conjugates?
A: We use R-PE in our conjugates.